Categories: News

Liopa reaches milestones in 2021 with lipreading technology

  • Expanded recognition of lipreading technology has increased inbound demand by more than 300%
  • First commercial sale achieved with Lancashire Teaching Hospitals NHS Trust
  • SRAVI won three recognitions this year, underscoring the importance of the technology

BELFAST, NORTHERN IRELAND – 20 December 2021Liopa reached milestones in 2021 with its lipreading technology, culminating in the first commercial sale of its SRAVI app to an NHS Trust. SRAVI is an ‘ultra-easy’ lipreading application that requires just a smartphone. It assists the voiceless by using AI algorithms to read words that they are mouthing.

Some of the milestones Liopa achieved in 2021 include:

More about Liopa’s SRAVI app
SRAVI brings a voice to the voiceless, by using AI algorithms to decipher speech from lip movements. Patients simply need to mouth words (from a predefined phrase list) into their smartphone’s camera, and SRAVI app will read out what they are trying to say. SRAVI stands for ‘speech recognition app for the voice impaired.’ Throughout the investigation into the app’s usefulness, it was proven that SRAVI reads lips with up to 95% accuracy. Further clinical evidence can be found at www.sravi.ai/evidence.html.

Notes to Editors

About Liopa’s SRAVI application:
SRAVI brings a voice to the voiceless through a mobile phone-based lipreading app. Find out more at www.sravi.ai.

About Liopa:
Liopa is one of the world’s only startups focused on automated lip reading, using deep learning techniques. Based in Belfast, Northern Ireland, Liopa has been borne out of PhD research at Queen’s University Belfast. Find out more at www.liopa.ai.

Press contact
Emily McDaid
Marketing Manager, Liopa
Emily.mcdaid@liopa.co.uk
+44 (0)745 609 4649

Ends

Source: RealWire

Staff

Recent Posts

HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference

HeartBeam system was recently cleared by US Food and Drug Administration (FDA) for comprehensive arrhythmia…

22 minutes ago

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused…

23 minutes ago

The National Children’s Cancer Society Awarded $1,000 Grant From Kars4Kids

This generous grant will directly benefit the NCCS's Beyond the Cure Ambassador Scholarship Program, which…

26 minutes ago

Honeycomb Clinic Positions for Public Offering

Medical Co-working space challenges broken healthcare system. HOUSTON, TEXAS / ACCESSWIRE / December 23, 2024…

26 minutes ago

Ensysce Biosciences Regains Full Compliance with Nasdaq

SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"…

26 minutes ago

Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson’s Disease

MIAMI, FL / ACCESSWIRE / December 23, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the…

26 minutes ago